Inside Coloplast: How a 90% Margin Biologics Division Quietly Transformed Chronic Care Economics
With 270,000 new patients joining its support program last year, Coloplast’s ecosystem is turning clinical intimacy into long-term dominance.
Trusted by 2,000+ private investors worldwide, Business Model Mastery is your daily ritual for building an edge over the market.
Each issue breaks down how great businesses truly operate—and what sets them apart by analyzing one company a day, helping you steadily build your own mental database of business models.
🧠 I handle the heavy lifting—digging into reports, filings, and key data—so you can focus on recognizing superior business models, comparing opportunities, and OUTTHINKING the market.
📖 With 160+ business models analyzed so far, you have a growing library of insights at your fingertips. Each analysis brings you closer to SHARPENING your edge and building the conviction to invest with clarity and confidence.
✅ If you haven’t yet, LOCK IN the lowest price before rates rise. The launch price has officially increased to $600/year — but for the next 10 spots only, you can still secure it for just $359 (40%+ permanent discount). This limited offer is valid until Sunday, May 18th, or until the final 10 spots are gone — whichever comes first.
➡️ The newsletter will remain daily—because consistent exposure is the fastest way to build a powerful mental database of business models. To make this habit easier to maintain, each issue will now begin with a sharp, clear Executive Summary, giving you the core insights in under a minute. You can go deeper when you have time—or stay on track even when you don’t. Like capital, knowledge compounds—small, daily insights lead to exponential returns. If you find this new format valuable, tap the ❤️ to let me know; your feedback directly shapes what stays.
Let’s begin.
EXECUTIVE SUMMARY
1️⃣ Recurring Demand Engine: Over 66% of the company’s business comes from lifelong chronic care segments like ostomy and continence, locking in consistent demand and patient retention. More than 270,000 new patients joined its personalized support program last year.
2️⃣ Margin Dominance in Biologics: The Kerecis division, using patented fish-skin grafts, operates with a 90%+ gross margin and grew 35% last year, targeting 20% operating margin by 2025 in the fastest-growing wound care subsegment.
3️⃣ Integrated Ecosystem Moat: Clinical platforms educate 30,000+ healthcare professionals across 19 markets, while direct-to-consumer services span 10+ countries—creating a triple lock across patient, clinician, and payer.
4️⃣ Global Manufacturing Edge: 70% of production is centralized in Hungary, with expansion into Costa Rica and Portugal set to handle 40–50% of global output by 2029, cutting cost pressure and diversifying geographic risk.
5️⃣ Disciplined Financial Structure: Maintains a 27% operating margin, 68% gross margin, and 15% ROIC, with free cash flow up 23% YoY after adjusting for one-time taxes—backed by 4% R&D spend fueling pipeline innovation.
Now, let’s step into the full article—where every detail comes together to reveal the complete picture. 👇🏻
There’s a company helping over 2 million people across 140 countries manage chronic medical conditions—conditions most of the world doesn’t want to think about. Catheters. Ostomy bags. Wound dressings made from fish skin. And yet, beneath these intimate, often-overlooked products lies one of the most intelligently structured business models in modern healthcare.
If you dig just a little deeper, you’ll discover a company with margins north of 90% in one division, a moat rooted in clinical data, and a commercial machine so efficient it turns user intimacy into loyalty and loyalty into dominance. Most investors don’t even know it exists.
Let’s break it open.
This Company Doesn’t Just Sell Products. It Owns the Relationship Between Patient, Professional, and Payer
At its core, the business is built around one goal: help people live better with chronic conditions. But it doesn’t stop at selling medical devices—it orchestrates care. Think of it like this: if most medical device companies are hardware vendors, this one is Apple. It owns the product, the service layer, the education, and the data loop.
Its revenue engine flows through five core categories:
• Ostomy Care—35% of revenue. Bags, plates, accessories for people living with a stoma.
• Continence Care—32%. Intermittent catheters and bowel management.
• Advanced Wound Care—15%. Dressings and biologics, including fish-skin grafts.
• Interventional Urology—10%. Devices for urological issues like erectile dysfunction and overactive bladder.
• Voice & Respiratory Care—8%. Voice prostheses and breathing support for neck stoma patients.
But product categories only tell part of the story.
Here’s what matters more: over 66% of the company’s revenue comes from chronic conditions that require lifelong, recurring purchases. These aren’t one-time transactions. They’re subscriptions to better quality of life. That’s where the economic power lies.
⸻
This Isn’t a Commodity Business—Because It Made Itself Impossible to Replace
Take Luja™. On the surface, it’s a catheter. But underneath, it’s a technology built on Microhole Zone Technology that allows full bladder emptying in one uninterrupted flow—reducing UTIs, discomfort, and user error. That single innovation created a category shift. Clinical data backed it. Urologists recommended it. Payers reimbursed it at higher rates.
Or look at Heylo™—a digital ostomy leakage notification system launched in the UK. It doesn’t just notify users of leakage—it gives them control. It’s the first of its kind. The company isn’t selling medical gear. It’s creating tools that change how patients experience chronic care—and then building the system around them.
Here’s why that’s an economic fortress: in this industry, payers decide what’s covered, healthcare professionals decide what’s recommended, and patients decide what they’ll use long-term. This company is the rare one that wins all three layers.
It trains over 30,000 healthcare professionals per year on its platform. Its Coloplast® Care program personally supports patients in over 30 countries. Its clinical data gives payers a reason to offer higher reimbursement. The competition is not just behind on product—they’re shut out of the ecosystem.
⸻
Let’s Talk Margins. One Division Has a Gross Margin Above 90%
That’s not a typo. The biologics division, powered by a company called Kerecis, produces wound grafts made from fish skin. These grafts are shelf-stable, easy to store, and clinically proven to accelerate healing. They’ve been added to over 50 insurance plans in the U.S., unlocking access to 115 million Americans.
In 2023, Kerecis grew 35%. Its operating margin is set to hit 20% by 2025. But here’s the real edge: these grafts are in the fastest-growing segment of the wound care market, expanding 6–8% annually. The fish-skin process is patented, the brand is medically trusted, and the production costs are exceptionally low.
Margins this high are almost unheard of in medtech. And yet, in this company, they’re the tip of the iceberg.
⸻
Geographic Spread: No Single Point of Failure, but One Region Dominates the Growth Narrative
The company doesn’t rely on any single country. Revenue is balanced across the U.S. (24%), the U.K. (14%), France (10%), and dozens of others. But look closer and something stands out: emerging markets are growing 15% annually, the highest of any region.
The U.S. is particularly strategic. Not only is it the largest healthcare market in the world—it’s also the epicenter of the company’s biologics push. Kerecis operates almost exclusively in the U.S., where reimbursement is high and clinician adoption is accelerating.
But risk lives here, too. Distribution challenges in North America led to temporary supply chain issues in 2024, forcing the company to invest in a new logistics hub. The result was a short-term drag on margins—but with a long-term payoff in resiliency and scalability.
⸻
Behind the Scenes: A Supply Chain So Efficient, It Became a Moat
More than 70% of the company’s products are manufactured in Hungary. That’s changing. It’s now scaling two new plants—one in Costa Rica, the other in Portugal—to diversify operations and reduce labor inflation.
The Portugal site alone spans 30,000 square meters and will be the largest facility in the company’s history, becoming operational by 2026. When fully ramped, Portugal and Costa Rica will account for 40–50% of global production.
There’s more. The company automated key manufacturing lines in Hungary and China, delivering a net labor efficiency gain of ~1,000 full-time equivalents in 2024. It’s also cutting procurement costs through a centralized supply optimization initiative launching in 2025.
This is how you protect gross margins—even when inflation and wage pressures rise.
⸻
Customer Lock-In: The Most Underestimated Advantage in the Business
Each year, over 270,000 new patients enroll in the company’s support program. This isn’t passive marketing—it’s behavioral infrastructure. Patients receive guidance, education, reminders, and reorder options tailored to their specific condition and lifestyle.
Once enrolled, switching becomes difficult—not because of contracts, but because of comfort. Add in clinician trust and favorable insurance coverage, and you’ve built a loyalty loop that’s deeply human, not just economic.
And it works. The company consistently ranks above industry benchmarks in patient engagement and healthcare professional preference.
⸻
The Numbers Behind the Power: This Is What Operating Discipline Looks Like
Let’s cut through the noise and get to what matters:
• Gross marginsits at 68%, even after accounting for biologics integration and cost inflation.
• Operating marginremains steady at 27%, with a roadmap to exceed 30% as Kerecis scales.
• Return on invested capital (ROIC)is a commanding 15%, down from 17% last year—but still strong, even after heavy capital investments.
• Free cash flow rebounded to DKK 3.9 billionafter adjusting for one-off tax effects—up 23% year over year.
• R&D spend holds at 4% of revenue, signaling consistent innovation without compromising profitability.
No single metric tells the story. But the combination does: this is a company that grows, reinvests, protects its margins, and delivers consistent returns—without gambling on hype cycles or tech mirages.
⸻
Why Competitors Can’t Just Walk In
You’d think a well-funded player could enter and win. But here’s the trap: the barrier isn’t just the product. It’s the entire stack—from clinical data to patient relationships, from manufacturing depth to payer alignment.
To match this company, a competitor would need:
• A portfolio across five specialized categories.
• IP-protected innovations like Luja and Kerecis fish skin.
• Relationships with 30,000+ clinicians across 19 countries.
• Direct-to-consumer infrastructure spanning 10+ markets.
• Patient support systems built country by country, culture by culture.
It would take a decade. And even then, you’d still need to earn trust. In intimate healthcare, trust is the real currency—and this company has been compounding it for over 65 years.
⸻
The Bigger Picture: Chronic Care Is the Next Wave of Compounding Healthcare Returns
The world is aging. Chronic conditions are rising. Healthcare systems are overwhelmed and desperate for solutions that lower cost while raising outcomes. This company doesn’t just meet that need—it builds platforms around it.
In a world of buzzwords, here’s what stands out: this is a business that wins by solving real problems, at scale, with systems that reinforce themselves the longer they run.
It’s not flashy. But that’s precisely why most investors miss it.
And that’s exactly why you shouldn’t.
⸻
Conclusion
If you’re looking for companies with economic moats you can’t see on a spreadsheet, start here. What looks like a catheter company is actually a high-margin, patient-anchored, multi-channel machine with operational leverage, intellectual property, and deeply entrenched customer habits.
The best part? It’s just getting started in high-growth segments like biologics and digital health. Most investors will ignore it.
You won’t.
Because now you understand what’s really underneath.
Let’s keep sharpening your edge, one business model at a time.
See you tomorrow.
✋🏼 P.S: Before you go, I have a few important messages to share with you. 👇🏻
Getting value from Business Model Mastery? Hit LIKE (❤️)—it’s how you shape what comes next.
Every issue breaks down how great businesses really work—exposing hidden revenue streams, competitive advantages, and the factors that keep them ahead. I do the deep research so you can spot opportunities before the market catches on.
But here’s the deal: Liking this isn’t just appreciation—it’s a signal. It tells me what’s resonating, what to double down on, and which insights sharpen your edge the most.
If this helped you see smarter, think sharper, and invest better, hit LIKE now—so I know to bring you more of it.
💡 Must-Reads You’ll Love
In Case You Missed Them: Our Most-Loved Must-Reads to Sharpen Your Edge 👇🏻
⏰ Your Limited-Time Offer
Right now, you can lock in a forever rate of $359/year—a permanent 40%+ discount from the regular $600/year. With only 10 spots originally available, just a few remain. Once they’re gone, the price rises—regardless of the deadline on Sunday, May 18th at 11:59 PM (California time). This isn’t just about saving money—it’s about securing a lasting edge. For less than a coffee a day, you’ll gain daily insights that break down how great businesses truly operate, analyzing one company at a time to help you steadily build a mental database of business models. I handle the heavy lifting—digging into reports, filings, and key data—so you can focus on recognizing superior business models, comparing opportunities, and outthinking the market.
And…
Payments are processed securely through Stripe, and your card won’t be charged until the subscription reaches $600/year—letting you lock in today’s discounted rate risk-free. While all past content is still free, it will soon become exclusive to paying subscribers. Subscribing now secures uninterrupted access at the current rate forever. This isn’t just a financial decision—it’s an investment in sharpening your thinking, understanding what sets winning businesses apart, and building a competitive edge that keeps you ahead of the market. Lock in your forever price today and start mastering business models to outthink—and outperform—other investors.
🚫 Check Your Spam Folder
Sometimes, emails with images or links end up in Spam or Promotions folders. If you don’t see the latest breakdown, please check there. Mark it as important, so you never miss a valuable insight. A single overlooked email could be the one that saves you from a big mistake or reveals an unexpected winner.
Disclaimer: This content is informational, not financial or professional advice. Investing involves potential loss, and by using this material, you agree to accept all risks and waive class-action rights. Full disclaimer is available on the About page.